Estrella Immunopharma, Inc.
ESLA
$0.7936
-$0.0428-5.12%
NASDAQ
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 29.76% | -4.52% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -14.50% | 741.19% | |||
| Operating Income | 14.50% | -741.19% | |||
| Income Before Tax | 14.50% | -741.19% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 14.54% | -741.55% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 14.54% | -741.55% | |||
| EBIT | 14.50% | -741.19% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 13.77% | -719.70% | |||
| Normalized Basic EPS | 13.76% | -714.46% | |||
| EPS Diluted | 13.77% | -719.70% | |||
| Normalized Diluted EPS | 13.76% | -714.46% | |||
| Average Basic Shares Outstanding | -0.87% | 2.83% | |||
| Average Diluted Shares Outstanding | -0.87% | 2.83% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||